Table 2.
Number of subjects/concentrations available for population pharmacokinetic modelling
| Group | No. of subjects | No. of concentrations | Median no. of concentrations per subject (range) |
|---|---|---|---|
| Healthy volunteers—tablets | |||
| CPG | 20 | 290 | 15 (12–15) |
| DDS | 20 | 295 | 15 (13–15) |
| CCG | 19 | 204 | 10 (7–14) |
| Healthy volunteers—solution | |||
| CPG | 23 | 340 | 15 (13–15) |
| DDS | 23 | 343 | 15 (14–15) |
| CCG | 23 | 238 | 10 (7–13) |
| Zambian adult patients | |||
| CPG | 65 | 65 | 1/subject |
| CPG (pre 2nd dose) | 65 | 35 | 1/subject |
| DDS | 65 | 65 | 1/subject |
| DDS (pre 2nd dose) | 35 | 35 | 1/subject |
| CCG | 58 | 58 | 1/subject |
| CCG (pre 2nd dose) | 28 | 28 | 1/subject |
| Gambian children patients | |||
| CPG | 65 | 118 | 1 (1–7)* |
| CPG (pre 2nd dose) | 41 | 94 | 1 (1–7)* |
| DDS | 66 | 117 | 1 (1–7)* |
| DDS (pre 2nd dose) | 40 | 91 | 1 (1–7)* |
| CCG | 58 | 89 | 1 (1–5) |
| CCG (pre 2nd dose) | 35 | 66 | 1 (1–5) |
*
One subject had two blood samples recorded at 1 h post dose.